Founder Lim Kok Wing Dies At 75

KUALA LUMPUR— Founder and President of Limkokwing University of Creative Technology, Lim Kok Wing, (right) died Tuesday.

He was 75.

The news of his death was announced by Limkokwing University in a statement.

“With deep sadness, we convey the passing of Professor Emeritus Dr Lim Kok Wing, our Founder President.

“A visionary, his career has been synonymous with creativity, and he assisted in developing innovative education globally, empowering especially the developing world.

“We are humbled by the loving condolences and support extended by so many, and ask for privacy as we mourn a man we are very proud of,” the statement read.

Lim was reported to have been hospitalised last week following a fall at his home.

Source: NAM NEWS NETWORK

S’pore Reviews Data On Anaphylaxis For mRNA Covid-19 Vaccines

SINGAPORE— Singapore is currently reviewing local and international safety data on vaccinating persons with a history of anaphylaxis (allergic reaction) due to food and other medicines, with a view to allowing this group to receive the mRNA COVID-19 vaccines safely.

In a statement late Monday, the republic’s Expert Committee on COVID-19 Vaccination said it intended to complete this review in the next two weeks.

Given the local and international data accrued, the Committee said it recommended that the medical eligibility for using the Pfizer-BioNTech or Moderna vaccines can be safely expanded.

The Committee had just recommended extending the use of Pfizer-BioNTech and Moderna to population subgroups previously restricted namely Pregnancy and Breastfeeding as well as Cancer Patients on Treatment.

As the accrued international data is reassuring, the Committee has also determined that it is safe for persons with a history of Severe Cutaneous Adverse Reactions (SCAR) to be vaccinated.

This group of persons were previously contraindicated against the Pfizer-BioNTech or Moderna COVID-19 vaccines, out of an abundance of caution, it said.

SCAR include Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, Drug Rash with Eosinophilia and Systemic Symptoms, Drug-induced Hypersensitivity Syndrome.

Source: NAM NEWS NETWORK

Third Giant Panda Cub Born In Malaysia

KUALA LUMPUR– Liang Liang, the female giant panda, on loan from China to Malaysia, has given birth to a third baby giant panda, the country’s wildlife department said, today.

The cub was born late yesterday, at the Giant Panda Conservation Centre, at Malaysia’s National Zoo near Kuala Lumpur, the department said in a statement.

The gender of the cub has yet to be determined, as it is being held under the care of its mother and cannot be approached, according to the statement, adding that, the keepers at the National Zoo are closely monitoring them over the next 24 hours.

The department said, the birth of the third giant panda cub is another success of the giant panda conservation effort, under the Giant Panda conservation cooperation programme inked between the governments of Malaysia and China in 2012, it said.

The parents, Xing Xing and Liang Liang, arrived in Malaysia in 2014, marking the 40th anniversary of diplomatic relations between Malaysia and China. Coincidently, the third baby panda was born on Monday, May 31, which marked the 47th anniversary of the establishment of diplomatic relations between the two countries.

The first Malaysian-born giant panda Nuan Nuan, was born on Aug 18, 2015, while a second, Yi Yi was born on Jan 14, 2018. Nuan Nuan returned to China in Nov, 2017, after turning two years old.

Source: NAM NEWS NETWORK

Royal Malaysian Air Force Detects Chinese Aircraft Flying Close To National Airspace

KUALA LUMPUR— The Royal Malaysian Air Force (RMAF) Monday detected 16 aircraft from the People’s Liberation Army-Air Force (PLAAF) flying close to the national airspace.

RMAF chief Gen Ackbal Abdul Samad said the suspicious flight of the PLAAF aircraft was detected by the RMAF Air Defence Radar from the Air Defence Centre in Sarawak at 11.53 am.

“The planes were detected flying in a ‘tactical in-trail ’formation at a distance of 60 nautical miles from each other. The long formation flew in the same pattern and direction using a single entry and exit point.

“They were later found to have changed the flight direction in the Beting Patinggi Ali airspace, which is of interest to the country,” he said in a statement Tuesday.

Ackbal said the planes were detected flying at altitudes of between 23,000 to 27,000 feet at speeds of about 530km/h through the Singapore Flight Information Region (FIR) before entering the Malaysian Maritime Zone (MMZ) airspace, Kota Kinabalu, Sabah FIR and then nearing about 60 nautical miles off the coast of the Sarawak region, which was feared to threaten national sovereignty.

He said the RMAF then placed the Hawk 208 aircraft from Squadron No 6 at the Labuan Air Base on standby.

“Surveillance via air defence radar continued on the aircraft, while several attempts were made to direct them to contact the Kota Kinabalu FIR air traffic control.

“When the instructions were not heeded and the aircraft were found to have crossed the Kota Kinabalu FIR border heading towards the national airspace, the RMAF launched interceptor planes at 1.33 pm to perform visual identification,” he said.

Ackbal said through the process, the RMAF identified the aircraft types as ‘Ilyushin Il-76’ and ‘Xian Y-20’.

“These types of aircraft are strategic transport aircraft and capable of carrying out various missions,” he said.

He said the incident was a serious threat to national sovereignty and aviation security based on the air traffic density in the airways within the Kota Kinabalu FIR.

“This incident was handled by the RMAF in particular, and the Malaysian Armed Forces in general, in accordance with the laws and regulations of the International Civil Aviation Organisation and the National Air Defence Strategy,” he said.

According to Ackbal, the Ministry of Foreign Affairs has taken note of this matter through the Ministry of Defence.

Source: NAM NEWS NETWORK

ฐานข้อมูลความรู้ด้านเภสัชกรรม DrugBank ขยายความครอบคลุมสู่ประเทศไทย

เอ็ดมันตัน, อัลเบอร์ตา, May 31, 2021 (GLOBE NEWSWIRE) — DrugBank ฐานข้อมูลความรู้ด้านเภสัชกรรมที่สมบูรณ์และทันสมัยที่สุดในโลก ได้ขยายความครอบคลุมเพื่อให้บริการลูกค้าทั่วโลกได้ดียิ่งขึ้น โดยมีการเพิ่มภูมิภาคใหม่อีก 7 ภูมิภาคเพื่อนำเสนอผลิตภัณฑ์ ได้แก่ ออสเตรีย โคลัมเบีย อินโดนีเซีย อิตาลี มาเลเซีย ไทย และตุรกี นอกเหนือจากความครอบคลุมที่มีอยู่ของ DrugBank แล้ว ลูกค้าสามารถเข้าถึงชุดข้อมูลยาใหม่ๆ สำหรับผลิตภัณฑ์ยาและข้อบ่งใช้ยาเฉพาะสำหรับแต่ละภูมิภาคใหม่

“ด้วยการขยายเพิ่มใหม่นี้ ฐานความรู้ด้านเภสัชกรรมของเราจะสามารถเข้าถึงได้และครอบคลุมมากขึ้น” Mike Wilson, CEO ของ DrugBank อธิบาย “ซึ่งจะช่วยให้ลูกค้าใหม่ทั่วโลกสามารถเข้าถึงการนำเสนอผลิตภัณฑ์ของเราได้มากขึ้น และช่วยให้ลูกค้าเดิมขยายตัวสู่ตลาดใหม่ๆ”

สำหรับลูกค้าซอฟต์แวร์ทางคลินิก เช่น ผู้ที่อยู่ในอุตสาหกรรมเวชระเบียนอิเล็กทรอนิกส์ (EMR) ลูกค้าจะสามารถใช้ภูมิภาคท้องถิ่นของตนเป็นจุดเริ่มต้นของข้อมูลทางคลินิกที่มีโครงสร้างของ DrugBank ทั้งหมดได้

ผู้ที่ดำเนินงานในหลายภูมิภาคจะสามารถเข้าถึงข้อมูลทางคลินิกผ่านการผสานรวมของภูมิภาคต่างๆ ด้วย API เดียว ลูกค้าจำนวนมากขึ้นทั่วโลกสามารถค้นหาและจัดเก็บยาที่ทันสมัยได้เร็วขึ้นและมีความแม่นยำมากขึ้น

ยิ่งไปกว่านั้น ความครอบคลุมที่เพิ่มขึ้นจะช่วยให้ลูกค้าที่ให้การสนับสนุนการตัดสินใจทางการแพทย์ขั้นสูงสามารถใช้ชุดข้อมูลที่ละเอียดของ DrugBank สำหรับการวิเคราะห์ข้อมูลและการสร้างข้อมูลเชิงลึกได้ DrugBank แก้ปัญหาที่สำคัญตั้งแต่ขั้นแรกสำหรับผู้ใช้เหล่านี้ เนื่องจากเป็นการกำหนดข้อมูลยาหลายภูมิภาคให้เป็นมาตรฐานโดยการแมปข้อมูลไปยังตัวระบุทั่วไป และอัปเดตการแมปเหล่านี้เป็นระยะ

“เราเห็นลูกค้าจำนวนมากขึ้นเรื่อยๆ ที่ไม่เพียงต้องการเครื่องมือค้นหายา แต่ยังต้องดำเนินการวิเคราะห์ข้อมูลที่ซับซ้อนเพื่อเปิดเผยข้อมูลเชิงลึกและคาดการณ์เพื่อปรับปรุงผลลัพธ์ด้านสุขภาพอีกด้วย” Craig Knox, CTO ของ DrugBank กล่าว “ชุดข้อมูลที่มีโครงสร้างของเราช่วยให้ลูกค้าข้ามขั้นตอนที่มักใช้เวลานาน ได้รับประโยชน์จากข้อมูลที่มีอยู่มากขึ้น และรับข้อมูลเชิงลึกได้เร็วขึ้น”

สำหรับข้อมูลเพิ่มเติมเกี่ยวกับ Clinical API ของ DrugBank โปรดไปที่ www.drugbank.com/clinical

เกี่ยวกับ DrugBank

DrugBank เพิ่มพูนสติปัญญาของมนุษย์เพื่อพัฒนาสุขภาพผู้คนทั่วโลก เราส่งมอบชุดผลิตภัณฑ์ที่ช่วยให้บริษัทด้านการดูแลสุขภาพสามารถปรับปรุงการส่งมอบการดูแลสุขภาพผ่านยาที่มีความแม่นยำหรือแอปพลิเคชันซอฟต์แวร์ทางคลินิก พร้อมกับเปิดเผยข้อมูลเชิงลึกโดยการใช้วิทยาศาสตร์ข้อมูลกับการค้นพบยา DrugBank Online ที่เป็นแหล่งข้อมูลที่เข้าถึงได้สาธารณะของเรา ผ่านการอ้างอิงในสื่อพิมพ์ทางวิชาการมากกว่า 13,000 ฉบับและนักวิจัยและผู้เชี่ยวชาญด้านสุขภาพหลายล้านคนทั่วโลกไว้วางใจเลือกใช้

หากต้องการเรียนรู้เพิ่มเติมเกี่ยวกับ DrugBank โปรดไปที่ www.drugbank.com

ติดต่อประชาสัมพันธ์:
Kelvin Chen
Marketing Director, DrugBank
kelvin@drugbank.com

Pharmaceutical Knowledge Database DrugBank Expands Coverage To Thailand

EDMONTON, Alberta, May 31, 2021 (GLOBE NEWSWIRE) — DrugBank, the world’s most complete and up-to-date pharmaceutical knowledge database, expands coverage to better serve global customers. Seven new additional regions have been added to its product offering including Austria, Colombia, Indonesia, Italy, Malaysia, Thailand, and Turkey. On top of DrugBank’s existing coverage, customers can access new drug datasets for drug products and drug indications, specific to each new region.

“With these new additions, our pharmaceutical knowledge base becomes even more accessible and comprehensive,” explains Mike Wilson, CEO of DrugBank. “It allows new customers around the world better access to our product offerings, and helps existing customers grow into new markets”.

For clinical software customers, such as those in the electronic medical records (EMR) industry, they can use their local region as an entry point to the rest of DrugBank’s structured clinical information.

Those who operate in multiple regions can access clinical information through any combination of regions with one single API. More customers around the world can now search and store up-to-date medications faster and with more accuracy.

Moreover, the expanded coverage lets customers who provide advanced clinical decision support to use DrugBank’s detailed datasets for data analysis and insight generation. DrugBank solves a critical first step, for such users, as it normalizes multi-region medication data by mapping them to common identifiers, and keeps these mappings updated periodically.

“We are seeing more and more customers who not only need a drug lookup tool but perform complex data analysis to uncover insights and make predictions to improve health outcomes,” says Craig Knox, CTO of DrugBank. “Our structured datasets essentially help them skip an often time-consuming step, get more value out of their existing data, and get to insights faster.”

For more information about DrugBank’s Clinical API, visit www.drugbank.com/clinical

About DrugBank

DrugBank augments human intelligence to improve the world’s health. We offer a suite of products that enable healthcare companies to improve healthcare delivery through precision medicine or clinical software application, while uncovering insights by applying data science to drug discovery. Our publicly accessible resource, DrugBank Online, has been cited in over 13,000 academic publications and is used by millions of researchers and health professionals globally.

To learn more about DrugBank, visit www.drugbank.com

Press Inquiries:

Kelvin Chen
Marketing Director, DrugBank
kelvin@drugbank.com

Anti-Palm Oil Campaign: WTO Approves Panel To Examine EU Delegated Regulation – Msian Minister

KUALA LUMPUR— Malaysia’s application for the setting up of a panel to examine the steps taken by the European Union (EU) in the implementation of the Delegated Regulation under the European Union Renewable Energy Directive 2018/2001 (EU RED II) has been approved by the World Trade Organisation (WTO).

Plantation Industries and Commodities Minister Dr Mohd Khairuddin Aman Razali said the second application was approved by a Dispute Settlement Body (DSB) meeting under the WTO last Friday after the first application was rejected by the EU on April 28.

He said Malaysia, which remained committed in pursuing legal action against the EU in line with the Cabinet’s decision on July 1, 2020, filed the case on Jan 15, 2021.

“As the world’s second largest producer of palm oil, Malaysia regrets the EU’s treatment of palm oil compared to other vegetable oils,” he said in a statement Monday.

Mohd Khairuddin said Malaysia’s action was necessary in protecting the interests of the country’s palm oil industry which has made a significant contribution to the country’s socio -economic development, especially to smallholders.

He said the ministry, in collaboration with the Attorney-General’s Chambers and the Ministry of International Trade and Industry, will undertake the necessary preparations to defend the country’s palm oil industry.

“The application was because of the lack of a solution during the consultations held with the EU on March 17, 2021,” he said.

Source: NAM NEWS NETWORK

1,052,145 Individuals Completed Two-Dose Vaccination As At Sunday – M’sian Health Minister

KUALA LUMPUR— A total of 1,052,145 individuals had completed taking two doses of vaccine under the National COVID-19 Immunisation Programme up to Sunday, said Health Minister Dr Adham Baba.

Dr Adham, in his tweet, said Dr Adham said 1,860,864 individuals had received the first dose, bringing the total number of doses administered to 2,913,009.

He said the five states with the highest number of people having received both doses were Selangor (139,427) followed by Sarawak (109,934); Perak (97,558); Kuala Lumpur (94,399) and Johor (92,231).

As at Sunday, 49.9 per cent or 12,117,091 individuals had registered to receive vaccine shots, with Selangor continuing to record the highest registrations at 3,223,832.

According to the immunisation programme plan, the first phase of administering the vaccine from February until April involved 500,000 frontliners.

The second phase which is from April until August involves 9.4 million senior citizens, those at risk and the disabled, while the third phase which is scheduled for May until February 2022, will involve those aged 18 and above as well as non-citizens with the target of 13.7 million or more.

Source: NAM NEWS NETWORK